Besides this last one and PCSK9 inhibitors, also IONIS-ANGPTL3-LRX (target: hepatic ANGPTL3 mRNA; NCT02709850) and AKCEA-APOCIII-LRX (target: hepatic APOC3 mRNA; NCT02709850) are in development in the atherosclerosis field. This evidence concerns the gene ANGPTL3 and atherosclerosis.